Email Alert | RSS    帮助

中国防痨杂志 ›› 2019, Vol. 41 ›› Issue (6): 700-704.doi: 10.3969/j.issn.1000-6621.2019.06.020

• 综述 • 上一篇    下一篇

抗结核药物药代动力学/药效学的研究及进展

赵皎洁,陆宇()   

  1. 101149 首都医科大学附属北京胸科医院 耐药结核病研究北京市重点实验室 北京市结核病胸部肿瘤研究所药物研究室
  • 收稿日期:2019-02-11 出版日期:2019-06-10 发布日期:2019-06-04
  • 通信作者: 陆宇 E-mail:luyu4876@hotmail.com
  • 基金资助:
    "重大新药创制"科技重大专项(2015ZX09102007-015);北京市医院管理局"登峰"人才培养计划(DFL20151501)

Research and progress of PK/PD for anti-tuberculosis drugs

Jiao-jie ZHAO,Yu LU()   

  1. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
  • Received:2019-02-11 Online:2019-06-10 Published:2019-06-04
  • Contact: Yu LU E-mail:luyu4876@hotmail.com

摘要:

结核病治疗需要联合使用多种药物且治疗时间较长,迫切需要研发抗结核新药。抗结核新药的研发成果十分有限,对现有药物体内外的药代动力学/药效学(pharmacokinetic/pharmacodynamic,PK/PD)进行研究,优化抗结核药物的使用,对提高疗效,减少耐药结核病的发生至关重要。作者主要对PK/PD研究方法及抗结核药物PK/PD特点进行综述,为临床优化抗结核药物治疗方案提供参考。

关键词: 抗结核药, 药代动力学, 剂量效应关系, 药物, 综述文献(主题)

Abstract:

Tuberculosis treatment requires a combination of multiple drugs and long-term treatment, therefore, it is urgent to develop new anti-tuberculosis drugs. The research and development of new anti-tuberculosis drugs are inadequate. Exploring the pharmacokinetic/pharmacodynamics (PK/PD) of existing drugs in vitro and in vivo and optimizing the use of anti-tuberculosis drugs are essential to improve treatment efficacy and reduce the occurrence of drug-resistant tuberculosis. This article reviewed the PK/PD research methods and characteristics of anti-tuberculosis drugs PK/PD, in order to provide reference for clinical optimization of anti-tuberculosis treatment.

Key words: Antitubercular agents, Pharmacokinetics, Dose-response relationship, drug, Review litera-ture as topic